title: The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
authors.affiliation: Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Marc R
authors.initials: MR
authors.lastname: Theoret
authors.forename: Yang-Min
authors.initials: YM
authors.lastname: Ning
authors.forename: Jenny J
authors.initials: JJ
authors.lastname: Zhang
authors.forename: Robert
authors.initials: R
authors.lastname: Justice
authors.forename: Patricia
authors.initials: P
authors.lastname: Keegan
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001378:Azasteroids / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D000068538:Dutasteride; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D018120:Finasteride; D000068538:Dutasteride